Floatz logo

Rosiglitazone

Type 2 Diabetes Mellitus

Yale UniversitySmall moleculePhase 4 / ApprovedDormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
89/ 100

Competitive context

142 Active assets in the Type 2 Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Liraglutide
RenJi Hospital
Phase 4BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB

View all 50 →

Same molecule, other indications

Rosiglitazone is also rated in:

Metabolic SyndromeDormant
BB
Indicative ·
71 / 100
View asset →
type 2 diabetes mellitusDormant
BB
Indicative ·
70 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →